New analysis reveals that identical prescription drugs can cost up to 2,347 times more in different hospitals across the U.S., with cancer medications like Keytruda ranging from $12,000 to $43,000, highlighting a systemic chaos in healthcare pricing that defies existing transparency rules and leaves patients vulnerable to unpredictable costs.
The price for the same prescription drug in U.S. hospitals can differ by more than $10,000, with variations reaching an astonishing 2,347 times between the lowest and highest costs, according to a new report from 3 Axis Advisors. This analysis leveraged publicly available hospital data to uncover a pricing landscape where one insurer might pay $1 for a drug while another pays $2,347 for the identical medication at a different facility.
This crisis did not emerge overnight. In 2021, the Centers for Medicare & Medicaid Services implemented the Hospital Price Transparency Rule, mandating hospitals to publicly disclose detailed standard charges for drugs. Yet, years later, the rule has done little to standardize prices or protect consumers from vast, inexplicable markups.
The Scale of Price Disparities: From Cancer Drugs to Common Medications
The report’s findings are not isolated anomalies but reflect a widespread dysfunction. Key examples illustrate the extreme range:
- Keytruda (cancer treatment): $12,000 to $43,000 for 200 milligrams.
- Opdivo (cancer treatment): $17,000 to $67,000 for 480 milligrams.
- Ocrevus (multiple sclerosis): $16,000 to $65,000.
- Tysabri (multiple sclerosis): $6,500 to $27,000.
These discrepancies are not merely theoretical. A patient obtaining Keytruda through United Healthcare in Colorado might pay $12,059, while the same drug in Massachusetts could cost $43,099. Similarly, Darzalez Faspro for myeloma treatment costs $9,311 in North Carolina versus $36,300 in Wisconsin. Even Tysabri varies from $6,477 with Cigna in Tennessee to $26,451 in New Jersey.
Why Insured Patients Often Pay More Than the Uninsured
Perhaps most counterintuitively, the report indicates that uninsured patients sometimes receive better prices than those with insurance. This stems from inconsistent billing methods, unclear contracts, and the use of different unit measurements (e.g., per milligram versus per vial), which obscure true costs for the majority of patients—those covered by insurance. As the report notes, “While there is often consistency in list prices presented to payers and patients, the majority of a hospital’s patients – those with insurance – face a confusing array of potential prices.”
Systemic Chaos: The Failure of Transparency
Antonio Ciaccia, president of 3 Axis Advisors, summed up the findings: “Hospital data revealed a new level of dysfunction that surprised even us drug pricing cynics. What we found wasn’t just complexity — it was systemic chaos that makes it nearly impossible for payers and patients to understand or predict what they’ll pay at the hospital.” The Hospital Price Transparency Rule has unveiled these variations but has failed to achieve meaningful standardization, usability, or affordability. The report estimates that price differences are “significantly large enough to theoretically fund travel expenses between the hospitals while still resulting in significant savings,” underscoring the absurdity of the current system.
Policy Responses and the Road Ahead
The Trump administration has pursued initiatives like TrumpRx, a prescription drug price transparency tool, and most-favored-nation pricing, which aims to align U.S. drug costs with the lowest prices in peer countries. President Trump claimed that securing agreements with 17 major manufacturers represents “the greatest victory for patient affordability in the history of American health care.” Advocates like Cynthia Fisher of Patient Rights Advocate support these efforts but stress that “Maximum price transparency with stronger standardization and enforcement will allow patients to shop, make informed choices, and be protected from overcharges.”
The report calls for structural reforms, including standardized billing based on units sold, consumer-friendly price search functions, and stricter CMS oversight. Without these, the pricing chaos will persist, turning essential medications into financial burdens for millions.
For the fastest, most authoritative analysis on breaking news and in-depth investigations, trust onlytrustedinfo.com to deliver clarity when it matters most.
